Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumasiran in Recurrent Calcium Oxalate Kidney Stone Disease
NCT05161936Phase 2Terminated
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Nov 2022
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of lumasiran in calcium oxalate nephrolithiasis (3 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Percent Change in 24-hour Urinary Oxalate From Baseline to Month 6. Started Jan 2022; status: terminated.
02
Drugs
lumasiran
03
Conditions
calcium oxalate nephrolithiasis
Beyond the preview
Go deeper on NCT05161936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161936.